Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial

<p>Proteomics: DE and Reactome of Cyt proteins</p>

Tallennettuna:

Bibliografiset tiedot
Päätekijä:	Andrés Elía (15055031) (author)
Muut tekijät:	Leo Saldain (15055034) (author), Silvia I. Vanzulli (15055037) (author), Luisa A. Helguero (15055040) (author), Caroline A. Lamb (14947288) (author), Victoria Fabris (15055043) (author), Gabriela Pataccini (15055046) (author), Paula Martínez-Vazquez (15055049) (author), Javier Burruchaga (15055052) (author), Ines Caillet-Bois (15055055) (author), Eunice Spengler (15055058) (author), Gabriela Acosta Haab (15055061) (author), Marcos Liguori (15055064) (author), Alejandra Castets (15055067) (author), Silvia Lovisi (15055070) (author), María F. Abascal (15055073) (author), Virginia Novaro (15055076) (author), Jana Sánchez (15055079) (author), Javier Muñoz (15055082) (author), José M. Belizán (15055085) (author), Martín C. Abba (14947131) (author), Hugo Gass (15055088) (author), Paola Rojas (10737201) (author), Claudia Lanari (14947294) (author)
Julkaistu:	2025
Aiheet:	Cancer Tumor Biology Clinical Research and Trials Breast Cancer Clinical Trial Results Phase II clinical trials Endocrinology Hormone signaling and inhibitors
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Tekijä: Andrés Elía (15055031)
Julkaistu: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Tekijä: Andrés Elía (15055031)
Julkaistu: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Tekijä: Andrés Elía (15055031)
Julkaistu: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Tekijä: Andrés Elía (15055031)
Julkaistu: (2025)

Supplementary Figure S1 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
Tekijä: Britt K. Erickson (15028112)
Julkaistu: (2025)

Supplementary Figure S2 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
Tekijä: Britt K. Erickson (15028112)
Julkaistu: (2025)

Supplementary Figure S3 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
Tekijä: Britt K. Erickson (15028112)
Julkaistu: (2025)

Supplementary Figure S4 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
Tekijä: Britt K. Erickson (15028112)
Julkaistu: (2025)

Supplementary Figure S5 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
Tekijä: Britt K. Erickson (15028112)
Julkaistu: (2025)

Supplementary Figure S6 from Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer
Tekijä: Britt K. Erickson (15028112)
Julkaistu: (2025)

Supplementary Figure 1 from A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor–Positive Breast Cancer: The BRACELET-01/PrE0113 Study
Tekijä: Amy S. Clark (15053473)
Julkaistu: (2025)

Supplementary Figure 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
Tekijä: Emmanuel F. Petricoin (22436166)
Julkaistu: (2025)

Supplementary Tables 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
Tekijä: Emmanuel F. Petricoin (22436166)
Julkaistu: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
Tekijä: Lixuan Wei (14962431)
Julkaistu: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Tekijä: Nigel Bundred (15046233)
Julkaistu: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Tekijä: Nigel Bundred (15046233)
Julkaistu: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Tekijä: Nigel Bundred (15046233)
Julkaistu: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Tekijä: Nigel Bundred (15046233)
Julkaistu: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Tekijä: Nigel Bundred (15046233)
Julkaistu: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Tekijä: Qingsheng Xu (17078830)
Julkaistu: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Tekijä: Qingsheng Xu (17078830)
Julkaistu: (2025)

Figure 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Figure 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Figure 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Figure 4 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Table 1 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Table 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Table 4 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Tekijä: Dejan Juric (15126249)
Julkaistu: (2025)

Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
Tekijä: Patrick M. Grierson (17535179)
Julkaistu: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Tekijä: John A. Ligon (15024477)
Julkaistu: (2025)

Supplementary Data 2 from Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Tekijä: Hee-Jin Jang (14958513)
Julkaistu: (2025)

Supplementary Figure 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma
Tekijä: Parul Agarwal (15132371)
Julkaistu: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Tekijä: Giuseppe Basile (15051269)
Julkaistu: (2025)

Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Tekijä: Kohei Shitara (15043443)
Julkaistu: (2025)

Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Tekijä: Kohei Shitara (15043443)
Julkaistu: (2025)

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Tekijä: Kohei Shitara (15043443)
Julkaistu: (2025)

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Tekijä: Kohei Shitara (15043443)
Julkaistu: (2025)

Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Tekijä: Kohei Shitara (15043443)
Julkaistu: (2025)

Table 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Tekijä: Kohei Shitara (15043443)
Julkaistu: (2025)